Background {#Sec1}
==========

Recurrent reciprocal chromosomal translocations have been observed in specific subtypes of B-cell lymphomas \[[@CR1], [@CR2]\]. Although the presence of t(8;14)(q24;q32) and t(14;18)(q32;q21) are hallmarks of Burkitt lymphoma (BL) and follicular lymphoma (FL), respectively, these translocations occur at different B-cell differentiation stages \[[@CR1], [@CR2]\]. The *IGH*-*BCL2* fusion resulting from t(14;18) is generated from the failure of VDJ recombination in the bone marrow (BM) at an early B-cell stage, whereas the *IGH*-*MYC* fusion resulting from t(8;14) almost always occurs as a consequence of the aberrant class-switch recombination in germinal centers (GCs) of lymphoid tissues \[[@CR1]--[@CR3]\].

B-cell lymphomas harboring concurrent translocations of 8q24/*MYC* mainly in combination with 18q21/*BCL2* are called "double-hit" lymphoma and now defined as "high grade B-cell lymphoma with *MYC* and *BCL2* and/or *BCL6* rearrangements (HGBL-MBR)" according to the current World Health Organization classification (WHO) of lymphoid neoplasms \[[@CR2], [@CR4]\]. HGBL-MBR is frequently found in diffuse large B-cell lymphoma (DLBCL) and BL-like B-cell lymphoma cases, which show poor prognosis when treated with standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), with a median survival of around 12 months \[[@CR5]--[@CR7]\]. Although the WHO classification defines HGBL-MBR as the terminal deoxynucleotidyl transferase (TdT)-negative mature B cell neoplasm in spite of the cell morphology \[[@CR4]\], several cases with acute lymphoblastic leukemia (ALL)-like disease of HGBL-MBR (AL-HGBL-MBR) have been reported incidentally \[[@CR8]--[@CR33]\]. AL-HGBL-MBR is clinically characterized as the acute onset disease with the initial manifestation of BM infiltration by blastoid B cells but lacks obvious tumors, suggestive of primary lymphoma lesions. However, the characteristics have not been fully elucidated. We herein present an AL-HGBL-MBR case and conducted a literature review using PubMed to clarify the feature of this disease.

Case presentation {#Sec2}
=================

The condition of a 69-year-old Japanese woman was good until she developed remittent fever for one week. She had no previous history of lymphoma and presented to our institution with fever and increasing systemic bone pain. A physical examination showed no lymphadenopathy or hepatosplenomegaly. Laboratory tests showed a white blood cell count of 4.7 × 10^9^/L, hemoglobin level of 119 g/L, platelet count of 104 × 10^9^/L, and lactate dehydrogenase (LDH) level of 12,623 IU/L. A peripheral blood smear revealed leukoerythroblastosis with 7.5% blastoid cells. F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) detected the relatively strong accumulation of FDG in the liver, spleen, vertebrae, and bilateral clavicles, humeri, ilia, and femora (maximum standardized uptake value (SUVmax) 4.8\~13.0) (Fig. [1a](#Fig1){ref-type="fig"}). A BM examination revealed that more than 90% of nuclear cells were medium-sized blastoid cells with fine chromatin (Fig. [1b](#Fig1){ref-type="fig"}). A flow cytometric analysis showed that the cells were positive for CD10, CD19, CD20, HLA-DR, and surface IgMκ, but were negative for CD3, CD5, CD13, CD33, CD34, and TdT. The patient was tentatively diagnosed with mature B-cell leukemia and admitted to our hospital. She received R-hyper CVAD/MA (rituximab plus cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, and cytarabine). Although her serum LDH levels decreased to approximately 1000 IU/L after two courses of the intensive regimen, blastoid cells remained in the BM. Therefore, we changed the regimen to dose-adjusted EPOCH-R (rituximab plus etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin). After two courses of dose-adjusted EPOCH-R, leukemic cells remained and lost the expression of CD20. She died seven months after the diagnosis because of disease progression.Fig. 1Radiological, cytological, histological, immunophenotypic, and cytogenetic findings of AL-HGBL. **a** F-18-fluorodeoxyglucose (FDG) positron emission tomography detected the strong accumulation of FDG in the liver, spleen, and whole-body bone areas. **b** Bone marrow preparations stained with Wright-Giemsa (WG) and hematoxylin-eosin (HE) detected sheets of blastoid cells with fine chromatin and only a few vacuoles. Leukemic cells were strongly positive for CD20, CD10, and BCL2, and weakly positive for BCL6. **c** The karyotype of bone marrow cells was examined using G-banding. Red arrowheads indicate the derivative chromosomes. **d** The FISH analysis of interphase cells confirmed that t(14;18)(q32;q21) resulted in fusion between *IGH* (green) and *BCL2* (red) and also that one *MYC* split signal (red) was located beside the two amplified *MYC* genes. In addition, the FISH analysis of metaphase cells indicated the amplification of *MYC* (red) at 8q24 in derivative chromosome 8 and did not fuse to *IGH* (green). White arrows indicate these aberrations. **e** SKY revealed that 8q24 and 19q13.1 were translocated to chromosomes 2 and 11, respectively. In addition, the loss of chromosome 17p was confirmed because derivative chromosome 22 contained chromosome 17q. White arrows indicate the derivative chromosomes and marker chromosomes detected by G-banding

Histological and immunohistochemical analyses on BM specimens {#Sec3}
=============================================================

We morphologically reviewed BM specimens using hematoxylin and eosin (HE) staining. Immunohistochemistry (IHC) was also performed on formalin-fixed, paraffin-embedded sections. The monoclonal antibodies used for IHC were CD10 (56C6) (Nichirei, Tokyo, Japan), CD20 (L26) (Dako, Glostrup, Denmark), BCL2 (124) (Dako), BCL6 (P1F6) (Nichirei), MIB-1 (Dako), and MYC (Y60) (Abcam, Cambridge, UK). The MIB-1 index was calculated as the percentage of MIB-1-stained nuclei, which were counted among total 500 nuclei in three different visual fields.

The BM was massively infiltrated by medium-sized blastoid cells with fine chromatin and inconspicuous nucleoli (Fig. [1b](#Fig1){ref-type="fig"}). There were no paratrabecular lymphocyte aggregates, which are typically observed in FL \[[@CR9], [@CR11]\]. The blasts were strongly positive for CD20, CD10, BCL2, and the MYC protein and weakly positive for BCL6, indicating a GC B-cell phenotype (Fig. [1b](#Fig1){ref-type="fig"}). The MIB-1 index was unexpectedly low, at approximately 60% (Fig. [1b](#Fig1){ref-type="fig"}). This case was not diagnosed with DLBCL and suspected to have AL-HGBL-MBR.

Cytogenetic and fluorescence in situ hybridization studies {#Sec4}
==========================================================

Standard G-banding and fluorescence in situ hybridization (FISH) analyses were performed. The probes used for the FISH analysis were a Vysis® LSI® *IGH*/*BCL2* dual-color, dual-fusion translocation probe, Vysis® LSI® *IGH*/*MYC*/CEP8 tri-color dual fusion probe, and Vysis® LSI® *MYC* dual-color breakapart rearrangement probe (Abbott Molecular, Des Plaines, IL). The FISH analysis was applied to interphase and metaphase cells. Spectral karyotyping (SKY) was also performed for the aid of the interpretation of G-banded metaphase cells.

A G-banding analysis of BM specimens detected a complex karyotype including t(14;18)(q32;q21) and add(8)(q24) (Fig. [1c](#Fig1){ref-type="fig"}). A chromosomal segment of an unknown origin was translocated to the telomeric side of 8q24. The karyotype was 46,X,-X,-2,-4,+7,-8,add(8)(q24),inv(9)(p12q13),-13,t(14;18)(q32;q21),-17,add(19)(q13.1),-22,+mar1,+mar2,+mar3,+mar4,+mar5,+mar6 \[18\] (Fig. [1c](#Fig1){ref-type="fig"}). The FISH analysis of interphase and metaphase cells confirmed the fusion between *IGH* and *BCL2* and the split and extra copies of *MYC* at 8q24 (Fig. [1d](#Fig1){ref-type="fig"}). Furthermore, SKY identified that 8q24 and 19q13.1 were translocated to chromosomes 2 and 11, respectively. G-banding and SKY confirmed the loss of chromosome 17p (Fig. [1c, e](#Fig1){ref-type="fig"}). Taken together, this case was diagnosed with AL-HGBL-MBR with the extra copies of *MYC* and loss of chromosome 17p.

Literature review {#Sec5}
=================

We selected the cases with BM involvement (at least ≥20% of nuclear cells) of non-centroblastic, non-immunoblastic TdT-negative blastoid B cells harboring both t(14;18)(q32;q21) and 8q24/*MYC* translocations, which was confirmed by G-banding and/or FISH analyses. The cases with either of them were excluded. Although secondary AL-HGBL-MBR arising from FL was also found, we selected only de novo cases to evaluate the survival from diagnosis because the onset and outcome were clearly recorded in each report.

We have identified further 47 de novo AL-HGBL-MBR cases from the published data (Table [1](#Tab1){ref-type="table"}).\[[@CR8]--[@CR33]\] The median age at presentation is 61 years (range, 27--86); the male/female ratio was 2.0. Although 10 cases (21%) had a modest mass lesion at extranodal sites, the rest showed the clinical picture of ALL. In addition, 14 (36%) of 39 available cases showed central nervous system involvement. Unlike BL, L2-type morphology according to the French-American-British classification was observed in 14 (33%) of 42 available cases (Table [1](#Tab1){ref-type="table"}). The immunophenotype of leukemic cells was positive for CD10, CD19, and CD20 in most cases (Table [1](#Tab1){ref-type="table"}). Cytogenetic studies showed that loss of 17p and translocations at 2p12--13, 3q27, 9p13 are frequently observed as additional chromosomal aberrations, and at least nine (20%) cases had loss of 17p (Table [1](#Tab1){ref-type="table"}). Most patients reported prior to 2003 received standard chemotherapy for ALL, whereas patients reported since 2003 were frequently treated with rituximab-combined chemotherapy for lymphomas (Table [1](#Tab1){ref-type="table"}). Nevertheless, 42 patients (88%) died because of disease progression at the time of publication. Median survival of 46 cases, the observation period of which is well documented, was only five months (range 0.1--18 months) from the diagnosis. Their survival distribution was illustrated in Fig. [2a](#Fig2){ref-type="fig"}. The survival curves were determined using the Kaplan-Meier method. All analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, ver.1.33) \[[@CR34]\]. There was no significant difference in survival between older (≥60 years, *n* = 25) and younger (\<60 years, *n* = 21) patients (log-rank test, *P* = 0.198) (Fig. [2b](#Fig2){ref-type="fig"}). Among the examined 46 cases, 44 cases received chemotherapy, and their survival durations were significantly improved by rituximab use (log-rank test, *P* = 0.0294) (Fig. [2c](#Fig2){ref-type="fig"}).Table 1Clinicopathologic features of published cases with de novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with *MYC* and *BCL2* and/or *BCL6* rearrangementsCase (ref. n)Age/sexExtramedullary lesion at presentationCNSFAB criteriaImmunophenotypeMain cytogenetic abnormalitiesFISH or gene analysisCurative therapySurvivalCD10CD19CD20sIg*IGH-BCL2MYC*1 (8)57/Fbone+L3++--NDt(8;22)(q24;q12^a^),t(14;18)(q32;q21)NANAALL regimen7 mo2 (9)74/Mpalate, L (cervical, pretracheal)--L3NA+NAμt(8;22)(q24;q11),t(14;18)(q32;q21)NANAALL regimen3 mo3 (9)37/Mnone--L2--++IgMλt(8;22)(q24;q11),t(14;18)(q32;q21)NANAALL regimen12 mo4 (9)73/Mnone+L3+++IgMκt(8;22)(q24;q11),t(14;18)(q32;q21)NANAALL regimen8 mo5 (10)62/MH, S--L3+++NDt(8;14)(q24;q32),t(14;18)(q32;q21)NANAALL regimen3 mo6 (11)35/Mnone--L3++NANDt(14;18)(q32;q21)GR (+)GR (+)ALL regimen0.3 mo7 (12)27/ML (IP, RP)+L3++--NDt(8;22)(q24;q11),der(14)t(14;18)(q32;q21)NANAALL regimen5 mo8 (13)67/Mnone--L3NA++IgGκt(8;22)(q24;q11),t(14;18)(q32;q21)NANAnone0.1 mo9 (14)71/Mnone--L3−/+++IgMλt(1;3;11)(q42.3;q27.1;q23.1),der(8)t(8;9)(q24.2;p13.3),t(14;18)(q32.3;q21.3),der(17)t(17;?)(p13;?)GR (+)GR (+)none0.1 mo10 (15)36/FIP mass--NA++NANDt(8;22)(q24;q11),t(14;18)(q32;q21)NAGR (−)ALL regimen3 mo11 (15)60 Mnone+L2NANANANAt(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18)(q32;q21)NAGR (−)ALL regimen6 mo12 (16)40/MGL, paravertebral mass--L2+++NAder(6)t(6;8)(q1?;q24),add(8)(q24),der(9)t(8;9)(q24;p1?),t(14;18)(q32;q21),del(17)(p11)NANAALL regimen1 mo13 (17)69/MH--L3--++IgMκder(7;17)(q10;q10),+der(8)t(8;14;18)(q24;q32;q22),add(14)(q32),del(18)(q21)GR (+)NAALL regimen5 mo14 (18)41/Fnone--L3+++NAt(2;3)(p12;q27),del(8)(q24),t(14;18)(q32;q21)GR (+)GR (+)ALL regimen10 mo15 (19)50/FGL--L2+++IgMκt(3;4)(q27;p13),t(8;14;18)(q24;q32;q21),+ider(8)(q10)t(8;14;18)(q24;q32;q21)GR (+)GR (+)ALL regimen0.1 mo16 (19)44/MGL, S+NA+++IgMκt(3;13)(q27;q14),t(8;22)(q24;q11),t(14;18)(q32;q21),+der(18)t(14;18)(q32;q21)GR (+)GR (−)NCVBP, IVAM, ASCT7 mo17 (19)46/FGL, S, Asc, PE+L2+++IgMκt(2;3)(p12;q27),add(8)(q24),der(14)t(8;14)(q24;q32),der(18)t(14;18)(q32;q21)GR (+)GR (+)ACVBP, allo-SCT3 mo18 (20)62/FnoneNAL3NANANANAt(2;8)(p12;q24),t(14;18)(q32;q21)NANAnone0.1 mo19 (21)48/MGL--L2NANANANAt(8;9)(q24,p13),t(14;18)(q32;q21)NANAR-CHOP3.5 mo20 (22)72/MH, S--L2+NA+IgGκt(8;9)(q24;p13),t(14;18)(q32;q21)NANAR-EPOCH4 mo21 (23)71/MS (mild)--L2--++γt(1;2)(q22--23;p13),t(8;14)(q24;q32),t(14;18)(q32;q22)GR (+)GR (+)ALL regimen2 mo22 (24)50/FL (axillary), SC mass--L3++NANDt(2;3)(p12;q27),t(8;22)(q24;q11),t(14;18)(q32;q21),-17fusion (+)split (+)ALL regimen7 mo23 (25)29/Mnone--L3+++NA+8,t(8;22)(q24;q11),t(14;18)(q32;q21)NAsplit (+)R-CHOP, R-ICE, R-hyper-CVAD/MA5 mo24 (25)72/Mnone--L3+++NAt(8;22)(q24;q11.2),t(14;18)(q32;q21)NANAR-hyper-CVAD/MA11 mo^b^25 (25)50/Fnone+L3+++NAt(8;22)(q24;q11),t(14;18)(q32;q21)fusion (+)split (+)R-hyper-CVAD/MA3 mo26 (25)32/ML (mesenteric)+L3+++NAt(1;3)(p32;q26.2),t(8;22)(q24;q11),add(14)(q32),t(14;18)(q32;q21)fusion (+)split (+)hyper-CVAD/MA8 mo27 (25)67/ML (P), small intestine+L3+++NAt(8;14)(q24;q32),der(8)t(8;14)t(14;18)(q32;q21),der(14)t(8;14),+add(14)(q32),i(17)(q10)fusion (+)split (+)R-hyper-CVAD/MA, velcade9 mo28 (25)61/ML (RP), colon, prostate+L3NANANANAt(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18)fusion (+)NAhyper-CVAD/MA, MOAP9 mo29 (25)42/Fsmall intestine, omentum, breast--L3+++NAt(8;14)(q24;q32),t(14;18)(q32;q21),der(17)t(10;17)(q22;q10)fusion (+)NAproMACECytaBOM, CHOP, ESHAP, hyper-CVAD/MA, SCT, RT12 mo30 (25)63/Mtestis, lip--L3+++NANAfusion (+)split (+)hyper-CVAD18 mo31 (26)57/FnoneNANA++--NAder(3)t(3;14;?)(q27;q32;?),t(8;14)(q24;q32),der(18)t(14;18)(q32;q21)fusion (+)split (+)CODOX-M/IVAC2.5 mo32 (26)60/MnoneNAL3+++Dt(2;8)(p12;q24),der(8)t(2;8)(p12;q24),t(14;18)(q32;q21),?i(17)(q10)fusion (+)split (+)hyper-CVAD, CODOX-M3 mo33 (26)63/MGL, S (mild)NAL3+++Dder(3)t(1;3)(q23;q27),t(8;22)(q24;q11),t(14;18)(q32;q21)fusion (+)split (+)CODOX-M/IVAC6 mo34 (26)76/FnoneNAL3--+NADt(8;22)(q24,q11),t(14;18)(q32;q21)fusion (+)split (+)VAD6 mo35 (26)59/FnoneNAL2+NANANAt(8;9)(q24;p13),t(14;18)(q32;q21)fusion (+)split (+)ALL regimen1.5 mo36 (26)69/ML (IP), HNAL3+++Dt(14;18)(q32;q21)fusion (+)split (+)ALL regimen1.5 mo37 (26)86/FnoneNAL2+++NDadd(9)(p13),t(14;18)(q32;q21)fusion (+)split (+)none0.5 mo38 (27)43/Fpancreas+L3+++IgMλt(8;14)(q24;q32),t(14;18)(q32;q21)fusion (+)split (+)R-CODOX-M/IVAC5 mo39 (28)61/MGL, S, PE--L3+++γt(3;5)(q27;q15),t(8;14;18)(q24;q32;q21),+der(8)t(8;14;18),+der(18)t(8;14;18)fusion (+)split (+)R-hyper-CVAD,NA^c^40 (29)42/ML (IP), S+L2+++κder(8)del(8)(q12.1q12.3)del(8)(q24.21q24.21)t(8;12)(q24.21;p12.1),der(12)del(12)(p12.1p12.1)t(8;12)(q24.21;p12.1),t(14;18)(q32;q21)fusion (+)split (+)R-CHOP, ALL regimen7 mo41 (30)72/Mbone, liver+NA+NA+NAt(3;8)(q27;q24),t(14;18)(q32;q21)fusion (+)split (+)ALL regimenNA^c^42 (31)64/ML (NA)--NA+NA+NANAfusion (+)split (+)R-EPOCH1.7 mo^c^43 (31)72/ML (NA)--NA+NA+NAt(3;22)(q27;q11.2),t(8;14)(q24;q32),t(14;18)(q32;q21)fusion (+)split (+)R-EPOCH1.6 mo^c^44 (32)74/Fnone+L2+++κ--8,del(11)(q23q25),del(13)(q12q14),t(14;18)(q32;q21),+18fusion (+)split (+)R-CHOP3 mo45 (32)67/Mcolon--L3++−/+κNAfusion (+)split (+)R-CHOP11 mo^d^46 (32)71/ML (mediastinal)--L3+++κder(8)t(8;14;18)(q24;q32;q21),der(14)t(8;14)(q24.1;q32),der(18)t(14;18)(q32;q21)fusion (+)split (+)R-EPOCH, R-ICE, ASCT14 mo47 (33)60/MGLNAL2+++λ+8,inv(8)(p11.2q24)×2,t(14;18)(q32;q21),-17fusion (+)split (+)R-hyperCVAD, ofatumumab + EPOCH18 mo48 (present case)69/Fnone--L2+++IgMκadd(8)(q24),t(14;18)(q32;q21),-17fusion (+)split (+), EC (+)R-hyper-CVAD/MA, R-EPOCH7 mo*Abbreviations*: *Ref n* reference number, *FAB criteria* blastoid cell morphology according to the French-American-British classification, *CNS* development of central nervous system involvement, *sIg* surface immunoglobulin, *M* male, *F* female, *L* lymphadenopathy, *H* hepatomegaly, *S* splenomegaly, *SC* subcutaneous, *IP* intraperitoneal, *RP* retroperitoneal, *GL* generalized lymphadenopathy, *Asc* ascites, *PE* pleural effusion, *P* pelvic, *ND* not detected, *D* detected, *NA* not available, *GR* gene rearrangement, *EC* extra copies, *ALL regimen* multidrug chemotherapy for acute lymphoblastic leukemia, *NCVBP* mitoxantrone, cyclophosphamide, vinblastine, bleomycin, and prednisone, *IVAM* ifosfamide, etoposide, cytarabine, and methotrexate, *ASCT* autologous stem cell transplantation, *ACVBP* doxorubicin, cyclophosphamide, vinblastine, bleomycin, and prednisone, *allo-SCT* allogeneic stem cell transplantation, *R* rituximab, *CHOP* cyclophosphamide, doxorubicin, vincristine, and prednisone, *EPOCH* etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, *ICE* ifosfamide, carboplatin, and etoposide, *hyper-CVAD/MA* cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with methotrexate and cytarabine, *MOAP* methotrexate, vincristine, asparaginase, and prednisone, *proMACEcytaBOM* prednisone, vincristine, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, and bleomycin, *ESHAP* etoposide, methylprednisolone, cytarabine, and cisplatin, *RT* radiation therapy, *CODOX-M/IVAC* cyclophosphamide, vincristine, doxorubicin, methotrexate alternating with ifosfamide, etoposide, and cytarabine, *VAD* vincristine, doxorubicin, and dexamethasone, *POMP* prednisone, vincristine, methotrexate, and mercaptopurine^a^This description is according to original work \[8\]^b^Alive (disease status was not described)^c^Alive with disease at the time of publication^d^Alive with no evidence of disease at the time of publication Fig. 2Survival duration of the collected de novo AL-HGBL-MBR cases. **a** Kaplan-Meier survival distributions of 46 cases. Median survival was five months \[95% CI 3--7\]. **b** There was no significant difference in the survival durations between older (≥60 years, *n* = 25) and younger (\<60 years, *n* = 21) patients (median five \[95% CI 3--7\] vs. six \[95% CI 3--9\] months, log-rank test, *P* = 0.198). **c** Among 44 cases receiving chemotherapy, the survival in patients treated with rituximab (*n* = 16) was significantly improved, compared with in patients treated without rituximab (*n* = 28) (median seven \[95% CI 3.5-NA\] vs. five \[95% CI 3--7\] months, log-rank test, *P* = 0.0294). All *P* values were two-tailed, and *P* \< 0.05 was considered significant

Discussion {#Sec6}
==========

Based on the previous history and histopathology, our case was diagnosed with de novo AL-HGBL-MBR. Bone pain at the initial presentation was likely caused by rapid cell proliferation and the sudden onset of the disease in the BM. The literature review revealed that around 80% of de novo AL-HGBL-MBL cases had a typical clinical picture of ALL, and the features of present case were consistent with those of ALL. The noticeable behavior of this case is the unresponsiveness to R-hyper CVAD/MA and dose-adjusted EPOCH-R, which are expected to be effective regimens for not only BL but also HGBL-MBR \[[@CR7], [@CR35]\]. Indeed, DLBCL-type HGBL-MBR is reported to have a better prognosis than that of BL-like HGBL-MBR, which seems to have common clinical features with AL-HGBL-MBR \[[@CR36]\]. The differences of cell morphology in HGBL-MBR may influence the therapeutic efficacy of the conventional regimens. The median survival of the collected cases suggests that AL-HGBL-MBR may show the most unfavorable prognosis in any type of B-cell lymphomas. Despite the disastrous consequence, the present review showed that rituximab use had a positive impact on survival in HGBL-MBR cases.

t(14;18)-harboring FL arising from GC B cells usually presents an indolent clinical behavior, while this type of lymphoma often undergoes clonal evolution.\[[@CR37]\] AL-HGBL-MBR also develops from FL, and the clinical features of secondary AL-HGBL-MBR are nearly the same as those of de novo cases \[[@CR9], [@CR11], [@CR15], [@CR32]\] The prognosis of secondary AL-HGBL-MBR is likewise very poor \[[@CR9], [@CR11], [@CR15], [@CR32]\]. Besides alterations in *MYC*, disruptions in p53 and p14^ARF^, and an additional 3q27/*BCL6* translocation are considered to be the dominant changes in transformed FL \[[@CR37]\]. These alterations overlap with those of de novo AL-HGBL-MBR cases \[[@CR9], [@CR11], [@CR15], [@CR32]\] Although these abnormalities may incrementally accumulate during disease progression in FL, our case suggest that t(14;18)-carrying B cells suddenly develop into AL-HGBL-MBR when they have simultaneously acquired gene rearrangements and the amplification of *MYC* as well as the loss of 17p at the BM. If not, t(14;18)-carrying B cells may develop into a common FL. Even though this acquisition is a temporally distinct event, the accumulation of additional genetic abnormalities in t(14;18)-carrying B cells may eventually develop AL-HGBL. This situation is similar to that of ALL with *BCR*/*ABL1*. ALL with *BCR*/*ABL1* develops primarily and also arises from the blast crisis of chronic myelogenous leukemia. In AL-HGBL-MBR, the first hit is t(14;18), while the aggressive nature may be provided by further aberrations including the deregulation of *MYC* and disruption of p53. Therefore, FISH analyses regarding *MYC* and *TP53* should be evaluated, when HGBL-MBR is suspected, in t(14;18)-harboring neoplasms.

The leukemic cells in the present case strongly expressed the MYC protein, which precludes entry into the G0 phase. However, many of them remained in the G0 phase, in which the MIB-1 antibody failed to stain the nucleus \[[@CR38], [@CR39]\]. This condition indicates that the G0/G1 switch regulation was also impaired in the present case. In spite of the overexpression of MYC, MIB-1 index in HGBL-MBR cases was reported to vary from 25% to 100% \[[@CR40], [@CR41]\]. The suboptimal response to the R-hyper CVAD/MA and EPOCH-R regimens may be explained by the existence of MIB-1-negative and BCL2-positive cells. Recent in vitro studies suggested that concurrent inhibition of BCL2 and MYC may have therapeutic potential for the treatment of AL-HGBL-MBR patients \[[@CR42], [@CR43]\]. This strategy may overcome the resistance to conventional chemoimmunotherapy.

Conclusions {#Sec7}
===========

Our case and a review of the literature indicate that de novo AL-HGBL-MBR is a rare but may be a distinct clinical condition in HGBL-MBR. AL-HGBL-MBR may be the most aggressive disease among all t(14;18)-harboring neoplasms. Because conventional chemotherapeutic regimens are ineffective, other therapeutic strategies, such as using inhibitors against BCL2 and MYC, may elicit the potential to overcome the chemoresistance. The further accumulation of molecular evidences to illustrate AL-HGBL-MBR is needed.
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:   Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

R-hyper CVAD/MA

:   rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate and cytarabine

SKY

:   Spectral karyotyping

SUVmax

:   Maximum standardized uptake value

TdT

:   Terminal deoxynucleotidyl transferase

WHO

:   World Health Organization classification
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